On March 5, 2024, Seres Therapeutics Inc announced that it has filed a definitive proxy statement with Securities and Exchange Commission, stating that it has received a shareholder proposal from Kenneth Steiner regarding Company board take each step necessary so that each voting requirement in Company charter and bylaws that calls for a greater than simple majority vote be replaced by a requirement for a majority of the votes cast for and against applicable proposals, or a simple majority in compliance with applicable law. In addition, the Company recommended the shareholder to vote against the proposal at the annual meeting of shareholders scheduled to be held on April 4, 2024.